BiotechTube

Asciminib

ApprovedActive
3 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Conditions

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Trial Timeline

Nov 28, 2024 → Nov 1, 2026

NCT ID
NCT06427811

About Asciminib

Asciminib is a approved stage product being developed by Novartis for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase. The current trial status is active. This product is registered under clinical trial identifier NCT06427811. Target conditions include Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase.

What happened to similar drugs?

1 of 7 similar drugs in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase were approved

Approved (1) Terminated (1) Active (5)
✅NilotinibNovartisApproved
❌NilotinibNovartisPhase 3
🔄NilotinibNovartisPhase 3
🔄Asciminib + NilotinibNovartisPhase 3
🔄Imatinib + Nilotinib + Bosutinib + Dasatinib + AsciminibNovartisPhase 3
🔄Blinatumomab + Blinatumomab + HyperCVADAmgenPhase 3
🔄Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimenAmgenPhase 3

Hype Score Breakdown

Clinical
20
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (8)

NCT IDPhaseStatus
NCT04360005Pre-clinicalActive
NCT07250087Phase 1Recruiting
NCT06629584Phase 2Recruiting
NCT06427811ApprovedActive
NCT06236724Phase 2Recruiting
NCT05384587Phase 2Active
NCT04795427Phase 2Completed
NCT03605277Phase 1Completed

Competing Products

20 competing products in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

See all competitors
ProductCompanyStageHype Score
Imatinib MesylateNovartisPhase 2
35
NilotinibNovartisPhase 3
32
NilotinibNovartisPhase 3
40
STI571 400 mg + STI571 600 mgNovartisPhase 2
35
Induction Phase + Re-Induction Phase + Post-Remission + MaintenanceNovartisPhase 2
42
nilotinibNovartisPhase 2
35
Asciminib + NilotinibNovartisPhase 3
44
imatinib mesylateNovartisPhase 2
35
Blinatumomab + AsciminibNovartisPhase 1/2
39
AsciminibNovartisPhase 1
36
Asciminib Pediatric formulation group + Asciminib Adult formulation groupNovartisPhase 1/2
39
Nilotinib + LDE225NovartisPhase 1
29
NilotinibNovartisApproved
43
Imatinib + Nilotinib + Bosutinib + Dasatinib + AsciminibNovartisPhase 3
44
BlinatumomabAmgenPhase 2
35
Treatment with blinatumomab given subcutaneously.AmgenPhase 2
42
Blinatumomab + Blinatumomab + HyperCVADAmgenPhase 3
47
Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimenAmgenPhase 3
47
BosutinibPfizerPhase 1/2
36
Bosutinib + BosutinibPfizerPhase 1
29